ModifiedUnitedHealthcarePolicy CS029PA.S

Cytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Pennsylvania Only)

This Pennsylvania-only UnitedHealthcare medical policy addresses use of ductal lavage, nipple aspirate fluid (NAF) cytology, and fiberoptic ductoscopy for breast cancer screening, diagnosis, or as tools to guide surgery; it applies to services rendered in Pennsylvania and to requests evaluated under Pennsylvania exceptions.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Pennsylvania Only)

Policy CodePolicy CS029PA.S

Change TypeRevised content and archived prior version

Effective DateAug 1, 2025

Next Review Date

Key ActionFor services in Pennsylvania, follow state PARP and plan-specific prior authorization rules when requesting ductal lavage, NAF cytology, or fiberoptic ductoscopy; nonconforming requests may be denied.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information

Archived previous policy version CS029PA.R

38.9%inadequate NAF samples

0.64NAF cytology sensitivity

0.97NAF cytology specificity

20studies in review

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Unproven / Not Medically Necessary

Not medically necessary / investigational statements

Primary stance: Ductal lavage, nipple aspirate fluid cytology, and fiberoptic ductoscopy (with or without ductal lavage) are unproven and not medically necessary for breast cancer screening, diagnosis, or as alternative tools to guide surgery due to insufficient evidence of efficacy.

Supported by systematic reviews, cohort and single-center studies, and NCCN guideline statement.

Evidence Synthesis / No definitive coverage criteria provided

Summary of clinical evidence and limitations (no explicit cover/deny rules provided in this section):

Evidence summary: No high-quality evidence demonstrates that ductoscopy improves breast cancer detection rates, earlier stage at diagnosis, or reduces mortality; ductoscopy detects many malignancies under broad definitions but cannot reliably discriminate benign from malignant findings. Studies are heterogeneous, often single-center, retrospective, and small; further studies are needed to substantiate outcome benefits.

References: Waaijer systematic review and multiple retrospective and prospective studies.

This policy explicitly lists the procedures considered in scope and not medically necessary: breast ductal lavage; breast ductal fluid aspiration and cytology (nipple aspirate fluid, NAF); and fiberoptic ductoscopy (with or without ductal lavage). These interventions are addressed for use in breast cancer screening, breast cancer diagnosis, or as alternative tools to guide surgery.

The FDA has stated in a Consumer Update that nipple aspirate tests are not substitutes for mammograms. Devices for collecting ductal fluid are listed under product code KNW on the FDA website, but FDA information is provided for context and does not itself determine coverage.

Ductal lavage, nipple aspirate fluid cytology, and fiberoptic ductoscopy are considered investigational and not medically necessary for breast cancer screening, diagnosis, or as alternative tools to guide surgery due to insufficient evidence of clinical benefit. Studies show low sensitivity, high proportions of inadequate or inconclusive samples, and technical limitations. Major practice guidance (NCCN) does not recommend routine use of ductal lavage or nipple smear cytology. There is also no high-quality evidence that fiberoptic ductoscopy improves breast cancer detection rates, leads to earlier stage at diagnosis, or reduces mortality.

Key gaps in the evidence include limited diagnostic accuracy (poor sensitivity for NAF cytology and low sensitivity/inconclusive results for ductal lavage), high rates of inadequate samples (meta-analysis mean inadequacy ~38.9%), heterogeneous and mostly small or single-center studies, and a lack of longitudinal data demonstrating improved management or oncologic outcomes. Fiberoptic ductoscopy studies are generally preliminary, technically focused, and do not demonstrate outcome benefits; peripheral ducts are often inaccessible and the procedure is technically challenging.

Covered Indications

Screening or diagnostic evaluation of breast cancer or as an alternative tool to guide surgery

Guideline indication: NCCN does not recommend ductal lavage and does not recommend routine nipple smear cytology for patients with nipple discharge without palpable symptom.

Reference: NCCN guidelines (2025).

Evaluation of pathologic nipple discharge and localization of intraductal lesions

Indications drawn from studies: Pathologic nipple discharge (PND), particularly when mammography and ultrasound are negative or non-diagnostic; intraoperative localization of discharging ducts; and evaluation/localization of intraductal lesions.

Multiple studies of FDS in PND and intraoperative settings report diagnostic accuracy but are limited by single-center and retrospective designs; HFUS may be preferred when it identifies lesion extent.

Not Covered

Summary: Not covered — breast ductal lavage, nipple aspirate fluid cytology (NAF), and fiberoptic ductoscopy are not covered for breast cancer screening, diagnosis, or to guide surgery because current evidence does not demonstrate meaningful clinical benefit and practice guidelines do not support routine use.

Coding

Applicable CPT Codes (reference)CPT

19499

Unlisted procedure, breast

High-risk definition (example studies)

Gail 5-year risk5-year Gail Risk score ≥ 1.7% used in cohort studies to define high-risk participants.

Personal historyPersonal history of breast cancer considered a high-risk feature in study cohorts.

Family historyStrong family history of breast cancer (even with Gail <1.7%) classified participants as high risk in studies.

Prior suspicious biopsyPrevious biopsy showing atypical ductal hyperplasia, atypical lobular hyperplasia, or lobular carcinoma in situ counted as high risk in examples.

Definitions

Ductal lavage (DL)

DefinitionDuctal lavage (DL) is an invasive procedure that removes ductal fluid by inserting a microcatheter into breast ducts via the nipple.

Specimen purposeCollected ductal fluid is used for cytologic evaluation of epithelial cells.

Procedure noteDL may require successful cannulation of ducts; failure to obtain fluid or insufficient epithelial content has been reported in clinical series.

Nipple aspirate fluid (NAF)

DefinitionNipple aspirate fluid (NAF) is fluid obtained from the nipple either noninvasively or via fine-needle aspiration for cytologic or molecular analysis.

Intended analysesNAF is used for cytologic examination and for measurement of protein biomarkers and local hormone levels in research settings.

Provider Actions & Administrative Notes

Prior Authorization

State‑Specific Applicability / Prior Authorization

This policy applies only to the state of Pennsylvania. Any requests for services that do not meet criteria set in the Pennsylvania Access to Care requirements (PARP) will be evaluated on a case‑by‑case basis. Refer to Pennsylvania Exceptions, Pennsylvania Code, Title 55, Chapter 1101 for regulatory details.

Policy is state‑specific: applies only in Pennsylvania

Prior Authorization

Check Plan Prior Authorization Requirements

Before providing services, check the member’s benefit plan and any applicable prior authorization (PA) requirements. UnitedHealthcare may use third‑party clinical tools (for example, InterQual®) and plan‑level rules that can affect coverage determinations.

Verify plan contract and PA rules for the member before scheduling or performing services
Third‑party criteria (e.g., InterQual®) may be applied by UnitedHealthcare

Prior Authorization

PA prior authorization applies to ductal lavage / NAF procedures

This policy’s prior authorization requirements for ductal lavage and NAF procedures apply to Pennsylvania; follow Pennsylvania PARP and contract rules when requesting authorization.

Policy explicitly applies only to Pennsylvania; prior authorization must align with state exceptions and contractual terms.

Prior Authorization

Confirm plan-specific prior authorization rules for FDS

For fiberoptic ductoscopy (FDS), verify plan-specific prior authorization requirements; UnitedHealthcare may use plan contracts and third-party criteria to determine coverage.

Check member plan for any prior authorization or utilization management rules before scheduling FDS.
Clinical study contexts (e.g., methylene blue injection) do not alter plan authorization requirements.

Contrast Rules

Billing Rule

Contrast agents — methylene blue mentioned; no other FDS contrast rules provided

No modality-specific contrast rules for FDS are described in the policy excerpt; the document notes intraoperative methylene blue injection has been used to identify discharging ducts during FDS.

Methylene blue injection was used immediately after FDS in Zhang et al. (2025) to identify discharging ducts for selective ductectomy.
There are no other contrast agent rules specified for FDS in this policy excerpt.

Frequency Limits

FDS frequency limits / technical success

Frequency limitsNo specific repeat-frequency limit is defined for FDS in the policy; frequency controls were not specified.

Technical success noteIn Filipe et al. (2020) ductoscopy was successful in 151 of 215 patients analyzed (70% technical success); failures were due to perforation, narrow ducts, retracted nipple, prior procedures, or total ductal occlusion.

Complications and toleranceReported mild postprocedural complications included pain (~14.8%) and mastitis (~2.3%); major complications were rare in the cited cohort.

Background

Cytologic analysis of epithelial cells from breast ductal fluid (obtained by ductal lavage, nipple aspiration, or sampled during ductoscopy) has been studied as a potential early indicator of breast cancer, but available data show important limitations. Nipple aspirate fluid cytology has poor sensitivity and a high proportion of inadequate samples, ductal lavage findings do not reliably predict cancer and yield many inconclusive results, and fiberoptic ductoscopy evidence is limited to feasibility and diagnostic-accuracy reports without demonstrated impact on outcomes. Major guidelines (NCCN) do not recommend routine use of these techniques for screening or for evaluation of nipple discharge without palpable findings.